发布求助
文献互助 智能选刊 最新文献

Nature biotechnology最新文献

筛选
英文 中文
Editor's pick: Bioptimus.
IF 44.5 1区 生物学
Nature biotechnology Pub Date : 2026-10-19 DOI: 10.1038/s41587-026-03345-4
Michael Eisenstein
{"title":"Editor's pick: Bioptimus.","authors":"Michael Eisenstein","doi":"10.1038/s41587-026-03345-4","DOIUrl":"https://doi.org/10.1038/s41587-026-03345-4","url":null,"abstract":"","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":" ","pages":""},"PeriodicalIF":44.5,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Structural variant detection across sequencing technologies. 跨测序技术的结构变异检测。
IF 44.5 1区 生物学
Nature biotechnology Pub Date : 2026-10-15 DOI: 10.1038/s41587-026-03332-9
Gaoyang Li, Yadong Liu, Anqi Zhang, Xiaoyi Lin, Zheng Hu, Bo Liu, Long Qian, Yadong Wang
{"title":"Structural variant detection across sequencing technologies.","authors":"Gaoyang Li, Yadong Liu, Anqi Zhang, Xiaoyi Lin, Zheng Hu, Bo Liu, Long Qian, Yadong Wang","doi":"10.1038/s41587-026-03332-9","DOIUrl":"https://doi.org/10.1038/s41587-026-03332-9","url":null,"abstract":"<p><p>Structural variants (SVs) are a major source of genomic diversity, yet their discovery remains challenging due to repetitive genomic contexts, alignment ambiguity and the trade-off between sequencing cost and read length. Here we introduce HitSV, which implements repetitiveness- and signature-density-aware breakpoint recognition coupled with precise haplotype-resolved local assembly, thereby enabling base-resolution SV reconstruction and genotyping in various sequencing technologies. On the HG002 benchmark, HitSV achieved 15-72% (long read), 10-36% (short read) and 12% (hybrid sequencing), respectively, higher genotype F1 scores than state-of-the-art SV callers. Applied to the 1KGP phase 4 cohort, HitSV expanded the SV callset by 31.5%, substantially reshaping allele-frequency landscapes. In a large Chinese long-read cohort, HitSV uncovered tandem-repeat-mobile-element composite arrays as a prevalent, multi-allelic class of complex SVs, highlighting composite repeat architectures as an important and previously underrecognized contributor to human structural variation.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":" ","pages":""},"PeriodicalIF":44.5,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149195697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proteomic aging clocks go to trial. 蛋白质组学衰老时钟进入试验阶段。
IF 44.5 1区 生物学
Nature biotechnology Pub Date : 2026-10-13 DOI: 10.1038/s41587-026-03361-4
Neil A Robertson, Tamir Chandra
{"title":"Proteomic aging clocks go to trial.","authors":"Neil A Robertson, Tamir Chandra","doi":"10.1038/s41587-026-03361-4","DOIUrl":"https://doi.org/10.1038/s41587-026-03361-4","url":null,"abstract":"","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":" ","pages":""},"PeriodicalIF":44.5,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149183478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles. 利用配体定向脂质纳米颗粒进行CAR自然杀伤细胞免疫治疗的体内工程研究。
IF 44.5 1区 生物学
Nature biotechnology Pub Date : 2026-10-13 DOI: 10.1038/s41587-026-03310-1
Yuang Chen, Julia Monkovic, Haseeb Mughal, Binlong Chen, Elina Thadhani, Patrick McMullen, Ava Self, Yuxuan Chen, Yizong Hu, Samuel Detmer, Min Chen, Anna Lapteva, Ria Kamat, Ashley Vernon, Robert Langer, Daniel G Anderson
{"title":"In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles.","authors":"Yuang Chen, Julia Monkovic, Haseeb Mughal, Binlong Chen, Elina Thadhani, Patrick McMullen, Ava Self, Yuxuan Chen, Yizong Hu, Samuel Detmer, Min Chen, Anna Lapteva, Ria Kamat, Ashley Vernon, Robert Langer, Daniel G Anderson","doi":"10.1038/s41587-026-03310-1","DOIUrl":"https://doi.org/10.1038/s41587-026-03310-1","url":null,"abstract":"<p><p>Targeted lipid nanoparticles (LNPs) offer a nonviral approach for in vivo cell engineering but efficient programming of natural killer (NK) cells remains underexplored. Here we develop NK cell-targeted LNPs (NtLNPs) using engineered biparatopic NK cell ligands to drive receptor-specific uptake and mRNA delivery. Lead NtLNPs achieve up to ~80% NK cell transfection with minimal off-target effects in mice. Systemic delivery of chimeric antigen receptor (CAR) mRNA using NtLNPs generates CAR NK cells in vivo. CD19-targeted CAR NKs completely deplete circulating B cells in healthy mice and CD3-targeted CAR NKs eliminate nearly all autoreactive T cells in an autoimmune hepatitis model, highlighting a potential advantage over CAR T therapies for T cell-driven disease. In solid tumors, NtLNPs targeting the inhibitory checkpoint NKG2A enhance antitumor efficacy by relieving Qa-1<sup>b</sup>-mediated immunosuppression. Lastly, we optimized NtLNPs for in vivo engineering of human CAR NK cells, enabling regression of two humanized hematologic malignancy models and establishing NtLNPs as a modular immunotherapy system.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":" ","pages":""},"PeriodicalIF":44.5,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149183456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The global patent landscape of CRISPR–Cas applications in medicine CRISPR-Cas在医学领域应用的全球专利格局。
IF 44.5 1区 生物学
Nature biotechnology Pub Date : 2026-10-12 DOI: 10.1038/s41587-026-03337-4
Yunfang Yu, Yan Zhang, Yanjun Xu, Cai Wen, Li Li, Tao Yu
{"title":"The global patent landscape of CRISPR–Cas applications in medicine","authors":"Yunfang Yu,&nbsp;Yan Zhang,&nbsp;Yanjun Xu,&nbsp;Cai Wen,&nbsp;Li Li,&nbsp;Tao Yu","doi":"10.1038/s41587-026-03337-4","DOIUrl":"10.1038/s41587-026-03337-4","url":null,"abstract":"An analysis of the CRISPR–Cas patent landscape is essential for understanding applications in depth and overcoming challenges strategically, thereby supporting a safer integration of CRISPR–Cas into clinical practice.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"44 10","pages":"1606-1615"},"PeriodicalIF":44.5,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ten years, tens of millions of cells 十年，几千万个细胞。
IF 44.5 1区 生物学
Nature biotechnology Pub Date : 2026-10-12 DOI: 10.1038/s41587-026-03365-0
{"title":"Ten years, tens of millions of cells","authors":"","doi":"10.1038/s41587-026-03365-0","DOIUrl":"10.1038/s41587-026-03365-0","url":null,"abstract":"As the Human Cell Atlas project enters its second decade, the question is no longer whether we can map human cells, it is what we will do with the map.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"44 10","pages":"1587-1588"},"PeriodicalIF":44.5,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41587-026-03365-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149169917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RevMed’s pancreatic cancer drug first 首先是RevMed的胰腺癌药物。
IF 44.5 1区 生物学
Nature biotechnology Pub Date : 2026-10-12 DOI: 10.1038/s41587-026-03363-2
{"title":"RevMed’s pancreatic cancer drug first","authors":"","doi":"10.1038/s41587-026-03363-2","DOIUrl":"10.1038/s41587-026-03363-2","url":null,"abstract":"","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"44 10","pages":"1591-1591"},"PeriodicalIF":44.5,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149167283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biotech news from around the world 来自世界各地的生物技术新闻。
IF 44.5 1区 生物学
Nature biotechnology Pub Date : 2026-10-12 DOI: 10.1038/s41587-026-03347-2
{"title":"Biotech news from around the world","authors":"","doi":"10.1038/s41587-026-03347-2","DOIUrl":"10.1038/s41587-026-03347-2","url":null,"abstract":"","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"44 10","pages":"1594-1594"},"PeriodicalIF":44.5,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149167377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expanding global access to synthetic biology 扩大全球对合成生物学的了解。
IF 44.5 1区 生物学
Nature biotechnology Pub Date : 2026-10-12 DOI: 10.1038/s41587-026-03338-3
Prakriti Karki, Sudarshan GC
{"title":"Expanding global access to synthetic biology","authors":"Prakriti Karki,&nbsp;Sudarshan GC","doi":"10.1038/s41587-026-03338-3","DOIUrl":"10.1038/s41587-026-03338-3","url":null,"abstract":"Democratizing synthetic biology requires reducing costs, improving logistics and distribution, developing local expertise, and motivating educators and students.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"44 10","pages":"1736-1740"},"PeriodicalIF":44.5,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149168574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genome editing 基因组编辑。
IF 44.5 1区 生物学
Nature biotechnology Pub Date : 2026-10-12 DOI: 10.1038/s41587-026-03324-9
{"title":"Genome editing","authors":"","doi":"10.1038/s41587-026-03324-9","DOIUrl":"10.1038/s41587-026-03324-9","url":null,"abstract":"Recent patents relating to systems, methods and compositions for use in genome editing.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"44 10","pages":"1616-1616"},"PeriodicalIF":44.5,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书